Jefferies Reiterates Buy Rating on argenx SE (ARGX)

Jefferies analyst Akash Tewari reiterated a Buy rating and $950.00 price target on argenx SE (NASDAQ: ARGX).

The analyst comments "Vyvgart's Ph3 TED is d/c'ed for futility after prespecified interim analysis. While ARGX prev flagged this as an interesting study, we had not modeled TED due to limited biological proof. Imptly, we agree w/ ARGX re: limited read across to Graves' Disease due to pathology differences. Ultimately, we still like ARGX & see meaningful upside next yr w/ 4 reg readouts + think 50k pt guide by '30 remains conservative Bottom line: Vyvgart's Ph3 UplighTED TED study will be discontinued for futility following IDMC recommendation & lack of efficacy seen in prespecified interim analysis of unblinded data from pts completing 24 weeks."

For an analyst ratings summary and ratings history on argenx SE click here. For more ratings news on argenx SE click here.

Shares of argenx SE closed at $877.94 yesterday.

You May Also Be Interested In

• Apple suing OpenAI over alleged misappropriation of trade secrets
• Holtec Nuclear Corporation files for initial public offering
• Scribe Therapeutics Files for Nasdaq IPO